Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRPR | P30550 | 18/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bombesin SCHEMBL29711302 | 0.94 | GRPR (0.76) | GRPR | |
| Bombesin SCHEMBL3049338 | 0.94 | GRPR (0.76) | GRPR | |
| SCHEMBL30783571 | 0.92 | GRPR (0.65) | GRPR | |
| Bombesin SCHEMBL29364598 | 0.87 | GRPR (0.66) | GRPR | |
| Bombesin SCHEMBL29353003 | 0.87 | GRPR (0.70) | GRPR | |
| SCHEMBL30798936 | 0.86 | GRPR (0.81) | GRPR | |
| SCHEMBL29356178 | 0.86 | GRPR (0.76) | GRPR | |
| SCHEMBL23482609 | 0.85 | GRPR (0.82) | GRPR | |
| SCHEMBL29565297 | 0.84 | GRPR (0.68) | GRPR | |
| SCHEMBL31738529 | 0.84 | GRPR (0.62) | GRPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250009911-A1 | DOTA-HYNIC-iPSMA AS A THERAPEUTIC RADIOPHARMACEUTICAL TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN | INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARES (MX) | 2025-01-09 | — | — | US | disclosed |
| US-12128114-B2 | 177Lu-DOTA-HYNIC-iPSMA as a therapeutic radiopharmaceutical targeting prostate-specific membrane antigen | INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARES (MX) | 2024-10-29 | — | — | US | disclosed |
| CN-112074526-B | 177Lu-DOTA-HYNIC-iPSMA as a therapeutic radiopharmaceutical | 国家核研究所 | 2024-02-20 | — | — | CN | disclosed |
| EP-3766893-B1 | 177LU-DOTA-HYNIC-IPSMA AS A THERAPEUTIC RADIOPHARMACEUTICAL TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN | INSTITUTO NAC DE INVESTIGACIONES NUCLEARES (MX) | 2023-07-19 | — | — | EP | disclosed |
| US-11547767-B2 | 99mTc-EDDA/HYNIC-iPSMA as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen | INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARES (MX) | 2023-01-10 | — | — | US | disclosed |
| EP-4083049-A2 | 99MTC-EDDA/HYNIC-IPSMA AS A RADIOPHARMACEUTICAL FOR DETECTING THE OVEREXPRESSION OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN | Instituto Nacional de Investigaciones Nucleares (MX) | 2022-11-02 | — | — | EP | disclosed |
| CN-109641924-B | As radiopharmaceuticals for detecting over-expression of prostate specific membrane antigen99MTC-EDDA/HYNIC-IPSMA | 国家核研究所 | 2022-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12128114-B2 | 177Lu-DOTA-HYNIC-iPSMA as a therapeutic radiopharmaceutical targeting prostate-specific membrane antigen | LPXN, PTMS, ANPEP | GRPR 43/4885 |
| US-20250009911-A1 | DOTA-HYNIC-iPSMA AS A THERAPEUTIC RADIOPHARMACEUTICAL TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, PTMS, DNPEP | GRPR 173/4885 |
| US-11547767-B2 | 99mTc-EDDA/HYNIC-iPSMA as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen | KLK3, EPS15, CD99 | GRPR 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.